Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) CFO Sells 120,000 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Rating) CFO Alicia Grande sold 120,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $16.53, for a total value of $1,983,600.00. Following the transaction, the chief financial officer now owns 27,442 shares in the company, valued at $453,616.26. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Alicia Grande also recently made the following trade(s):

  • On Tuesday, November 15th, Alicia Grande sold 60,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $15.77, for a total value of $946,200.00.
  • On Friday, September 23rd, Alicia Grande sold 60,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $11.90, for a total value of $714,000.00.
  • On Friday, September 16th, Alicia Grande sold 90,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $13.50, for a total value of $1,215,000.00.
  • On Wednesday, September 14th, Alicia Grande sold 50,000 shares of Catalyst Pharmaceuticals stock. The shares were sold at an average price of $15.57, for a total value of $778,500.00.
  • On Monday, August 29th, Alicia Grande sold 57,000 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $14.20, for a total value of $809,400.00.
  • On Friday, August 26th, Alicia Grande sold 11,095 shares of Catalyst Pharmaceuticals stock. The stock was sold at an average price of $14.40, for a total value of $159,768.00.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $17.03 on Thursday. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of 27.92 and a beta of 1.27. The stock’s 50 day moving average price is $13.72 and its 200-day moving average price is $11.05. Catalyst Pharmaceuticals, Inc. has a one year low of $5.24 and a one year high of $17.76.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. HC Wainwright boosted their target price on Catalyst Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Thursday, August 11th. Truist Financial boosted their price objective on Catalyst Pharmaceuticals from $12.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday, August 11th. Roth Capital cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $10.00 to $15.50 in a research note on Wednesday, August 24th. Piper Sandler boosted their price objective on Catalyst Pharmaceuticals to $18.00 in a research note on Wednesday, November 16th. Finally, StockNews.com cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.13.

Institutional Trading of Catalyst Pharmaceuticals

Large investors have recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 24.2% in the second quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 822 shares during the period. Covestor Ltd boosted its holdings in shares of Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $62,000. KBC Group NV purchased a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $106,000. Finally, Point72 Hong Kong Ltd boosted its holdings in shares of Catalyst Pharmaceuticals by 63.0% in the first quarter. Point72 Hong Kong Ltd now owns 9,670 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 3,738 shares during the period. Hedge funds and other institutional investors own 74.16% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

(Get Rating)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Read More

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.